Study shows how streptococcal bacteria can be used to fight colon cancer

May 20, 2014
Study shows how streptococcal bacteria can be used to fight colon cancer
Western University researchers Dr. David Hess and Dr. John McCormick and lead author Kelcey Patterson show how the bacteria primarily responsible for causing strep throat can be used to fight colon cancer. By engineering a streptococcal bacterial toxin to attach itself to tumor cells, they are forcing the immune system to recognize and attack the cancer. Credit: Schulich School of Medicine & Dentistry, Western University

Researchers at Western University (London, Canada) have shown how the bacteria primarily responsible for causing strep throat can be used to fight colon cancer. By engineering a streptococcal bacterial toxin to attach itself to tumour cells, they are forcing the immune system to recognize and attack the cancer.

Kelcey Patterson, a PhD Candidate at Western and the lead author on the study, showed that the engineered bacterial toxin could significantly reduce the size of human tumours in mice, with a drastic reduction in the instances of metastasis. By using mouse models that are stripped of their immune system, they were able to create a 'humanized mouse' – one that would not only grow human , but would also support a human immune system, to test the anti-cancer immunotherapy.

The work was directed by John McCormick, PhD, an Associate Professor in the Department of Microbiology and Immunology and Scientist at the Lawson Health Research Institute. "Our team has been studying these called 'superantigens' for their role in bacterial infections. But we are now utilizing the power of these toxins to re-direct the to go after ." McCormick says their research provides important pre-clinical evidence that this may work in humans. "This work represents a 'next-generation immunotoxin' that we hope will eventually lead to a new class of cancer therapeutic."

The research was funded by the Canadian Institutes of Health Research. Jennifer Dixon Pittaro, Peter Bastedo, David Hess and Mansour Haeryfar all contributed to the paper entitled "Control of established colon cancer xenografts using a novel humanized single chain antibody-streptococcal superantigen fusion protein targeting the 5T4 oncofetal antigen."

McCormick and his colleagues have now received a new grant from the Cancer Research Society to develop different toxin and antibody combinations to fight other types of cancer.

More information: www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0095200

Related Stories

Unlocking secrets of breast tissue

April 8, 2014

A unique population of microbes in the female breast may lay the groundwork for understanding how this bacterial community contributes to health and disease, according to a new study out of Western University (London, Canada). ...

Recommended for you

New treatment options for a fatal leukemia

July 27, 2015

In industrialized countries like in Europe, acute lymphoblastic leukemia is the most common form of cancer in children. An international research consortium lead by pediatric oncologists from the Universities of Zurich and ...

Modified DNA building blocks are cancer's Achilles heel

July 22, 2015

In studying how cells recycle the building blocks of DNA, Ludwig Cancer Research scientists have discovered a potential therapeutic strategy for cancer. They found that normal cells have highly selective mechanisms to ensure ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.